An update from Y-Mabs Therapeutics (YMAB) is now available.
Y-mAbs Therapeutics, Inc. has appointed Peter Pfreundschuh as its new Chief Financial Officer and Treasurer, bringing a wealth of biotech finance experience from his previous leadership roles. Pfreundschuh is taking over from Bo Kruse and is set to receive a competitive package including a $500,000 salary, stock options, bonuses, and comprehensive benefits. His appointment is framed within an employment agreement that details severance benefits under various conditions, underscoring the company’s strategic financial leadership transition.
For detailed information about YMAB stock, go to TipRanks’ Stock Analysis page.
